THE 3’ END PROTHROMBIN GENE VARIANTS IN SERBIAN
PATIENTS WITH IDIOPATHIC THROMBOPHILIA
Aradjanski M1, Djordjevic V1, Pruner I1,*, Tomic B1, Gvozdenov M1, Kovac M2,3, Radojkovic D1
*Corresponding Author: Dr. Iva Pruner, Institute of Molecular Genetics and Genetic Engineering, Vojvode Stepe
444A, PO Box 23, 11010 Belgrade, Serbia. Tel: +381-11-397-6658. Fax: +381-11-397-5808. E-mail: iva.pruner@
gmail.com
page: 43
|
|
REFERENCES
1. Colman RW, Clowes AW, George JN, Goldhaber
SZ, Marder VJ. Overview of hemostasis. In: Colman
RW, Marder VJ, Clowes AW, George JN,
Goldhaber SZ. Haemostasis and Thrombosis:
Basic Principles and Clinical Practice, 5th ed.
Philadelphia, PA: Lippincott Wiliams & Wilkins.
2006: 2-15.
2. White RH. The epidemiology of venous thromboembolism.
Circulation. 2003; 107(23 Suppl
1): 14-18.
3. Rosendaal FR. Venous thrombosis: Prevalence
and interaction of risk factors. Haemostasis.
1999; (Suppl S1): S1-S9.
4. Griffin JH, Evatt B, Wideman C. Anticoagulant
protein C pathway defective in majority
of thrombophilia patients. Blood. 1993; 82(7):
1989-1993.
5. Egeberg O. Inherited antithrombin III deficiency
causing thrombophilia. Thromb Diath Haemorrh.
1965; 13: 516-530.
6. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ,
Wideman C. Deficiency of protrombin C in congenital
thrombotic disease. J Clin Invest. 1981;
68(5): 1370-1373.
7. Comp PC, Nixon RR, Cooper MR, Esmon CT.
Familial protein S deficiency is associated with
recurrent thrombosis. J Clin Invest. 1984; 74(6):
2082-2088.
8. Cushman M. Inherited risk factors for venous
thrombosis. Hematology Am Soc Hematol Educ
Program 2005: 452-457.
9. März W, Nauck M, Wieland H. The molecular
mechanisms of inherited thrombophilia. Z Kardiol.
2000; 89(7): 575-586.
10. Kalafatis M, Rand MD, Mann KG. The mechanism
of inactivation of human factor V and
human factor Va by activated protein C. J Biol
Chem. 1994; 269(50): 31869-318680.
11. Bertina RM, Koeleman BPC, Koster T, Rosendaal
FR, Dirven RJ, de Ronde H, et al. Mutation
in blood coagulation factor V associated with
resistance to activated protein C. Nature. 1994;
369(6475): 64-66.
12. De Stefano V, Chiusolo P, Paciaroni K, Leone G.
Epidemiology of factor V Leiden: Clinical implications.
Semin Thromb Hemost. 1998; 24(4):
367-379.
13. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer
P, Vetter B, Hentze MW, et al. Increased
efficiency of mRNA 3’ end formation: a new
genetic mechanism contributing to hereditary
thrombophilia. Nat Genet. 2001; 28(4): 389-392.
14. Danckwardt S, Hentze MW, Kulozik AE. 3’ End
mRNA processing: Molecular mechanisms and
implications for health and disease. EMBO J.
2008; 27(3): 482-498.
15. Danckwardt S, Gehring NH, Neu-Yilik G,
Hundsdoerfer P, Pforsich M, Frede U, et al. The
prothrombin 3’ end formation signal reveals a
unique architecture that is sensitive to thrombophilic
gain-of-function mutations. Blood. 2004;
104(2): 428-435.
16. Danckwardt S, Hartmann K, Gehring NH, Hentze
MW, Kulozik AE. 3’ End processing of the
prothrombin mRNA in thrombophilia. Acta Haematol.
2006; 115(3-4): 192-197.
17. Flaujac C, Conard J, Horellou MH, Le Flem L,
Samama MM. Atypical mutations of the prothrombin
gene at positions 20,209 and 20,218,
and a novel mutation at position 20,219. Report
on 10 patients. J Thromb Haemost. 2007; 5(5):
1064-1068.
18. Warshawsky I, Hren C, Sercia L, Shadrach B,
Deitcher SR, Newton E, et al. Detection of a
novel point mutation of the prothrombin gene at
position 20209. Diagn Mol Pathol. 2002; 11(3):
152-156.
19. Hooper C, Roberts S, Dowling N, Austin H,
Lally C, Whitsett C. The prevalence of the
prothrombin gene variant C20209T in African-
Americans and Caucasians and lack of association
with venous thromboembolism. Thromb
Res. 2006; 118(6): 767-768.
20. Ceelie H, Bertina RM, van HylckamaVlieg A,
Rosendaal FR, Vos HL. Polymorphisms in the
prothrom-bin gene and their association with
plasma prothrombin levels. Thromb Haemost.
2001; 85(6): 1066-1070.
21. Balim Z, Kosova B, Falzon K, Bezzina Wettinger
S, Colak Y. Budd-Chiari syndrome in a patient
heterozygous for the point mutation C20221T
of the prothrombin gene. J Thromb Haemost.
2003; 1(4): 852-853.
22. Pérez-Ceballos E, Corral J, Alberca I, Vayá A,
Llamas P, Montes R, et al. Prothrombin A19911G
and G20210A polymorphisms’ role in thrombosis.
J Haematol. 2002; 118(2): 610-614.
23. Martinelli I, Battaglioli T, Tosetto A, Legnani C,
Sottile L, Ghiotto R, et al. Prothrombin A19911G
polymorphism and the risk of venous thromboembolism.
J Tromb Haemost. 2006; 4(12): 2582-
2586.
24. von Ahsen N, Oellerich M. The intronic prothrombin
19911A>G polymorphism influences
splicing efficiency and modulates effects of the
20210G>A polymorphism on mRNA amount
and expression in a stable reporter gene assay
system. Blood. 2004; 103(2): 586-593.
25. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen
CJ. The association of prothrombin A19911G
polymorphism with plasma prothrombin activity
and venous thrombosis: results of the MEGA
study, a large popula-tion-based case-control study.
J Thromb Haemost. 2006; 4(12): 2587-2592.
26. Souto JC, Almasy L, Borrell M, Blanco-Vaca F,
Mateo J, Soria JM, et al. Genetic susceptibility to
thrombosis and its relationship to physiological
risk factors: the GAIT study. Genetic analysis
of idiopathic thrombophilia. Am J Hum Genet.
2000; 67(6): 1452-1459.
27. Djordjevic V, Pruner I, Kovac M, Miljic P, Antonijevic
N, Kojic S, et al. Three novel 3’ end
pro-thrombin gene polymorphisms and their
association with thrombophilia (abstract). J
Thromb Haemost. 2011; 9(Suppl 2): 873S.
|
|
|
|
 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
